Thus, this combination may be active in other scenarios where cells have demonstrated resistance, e.g. Trastuzumab and lapatinib resistant HER2+ breast cancer, hormone resistant ER+ breast cancer, hormone resistant PR+ prostate cancer, as well as triple negative breast cancers. Here, ERBB2 is linked to breast carcinoma.